Photys Therapeutics

Photys Therapeutics is a proprietary chimeric small molecules platform company that develops novel bifunctional medicines for fine-tuned control of protein post-translational modifications.

Photys’ proprietary bifunctional small molecules platform unlocks fine-tuned control of protein post-translational modifications, going beyond degradation to restore protein function, repair signaling, and amplify endogenous disease-fighting mechanisms.

Photys founded in 2021 by Longwood Fund and Dr. Amit Choudhary of Brigham and Women’s Hospital and the Broad Institute of MIT and Harvard. The company is headquartered in Cambridge, MA.


Photys is advancing Phosphorylation Inducing Chimeric Small Molecules (PHICS), a proprietary new class of bifunctional medicines that direct and repair protein phosphorylation to treat a range of diseases including cancer, immune, metabolic, and rare diseases.


PHICS can induce precise phosphorylation at native and/or non-native sites, modulating key functions including activation, stabilization, trafficking, localization, phospho-antigen presentation, inactivation, degradation and interactions of proteins.


Photys has raised $75M in a Series A funding on Sep 08, 2022. The round was led by MPM Capital and joined by Omega Funds, Longwood, 8VC, Arkin Bio, Mass General Brigham Ventures, Merck & Co., Eli Lilly and Company, MRL Ventures Fund, and others.



  • Year founded: 2021
  • Funding Info: $75M over 1 Round (Funding Type: Seires A)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Cambridge
  • State: Massachusetts
  • Country: United States
Related businesses